Please login to the form below

Not currently logged in
Email:
Password:

AbbVie rethinks Shire merger in light of US tax crackdown

Follows action to discourage 'inversion deals' aimed at reducing corporate tax rates
shire abbvie logos

New tax measures announced by the US Department of Treasury have caused AbbVie to rethink its deal to take over Ireland-based Shire.

AbbVie said its board plans to meet next week in order to discuss the company's $55bn bid for Shire, which was partly influenced by the prospect of having a base in the UK island of Jersey, which has a much lower corporate tax rate compared to AbbVie's US home.

However, this plan has been somewhat spoiled by an announcement by the US Government last month to change the country's tax regulations in order to discourage such 'tax inversion' deals, which have grown in popularity over the past few years as companies look to cut costs.

Tax inversion deals have become particularly prevalent in the pharma industry, with companies like Pfizer, Mylan, Endo and Actavis all proposing or confirming deals in order to gain headquarters in a European country with a lower corporate tax rate. Outside healthcare, large companies like Burger King and cable company Liberty Global have also adopted similar measures.

These deals have criticised by US politicians as being 'unpatriotic' and President Barack Obama has said he will halt their uptake.

Recent US tax inversion deals

Year
Acquirer
Target
New company tax domicile
2010
Valeant
Biovail
Canada
2011
Alkermes
Elan
Ireland
2012
Jazz
Azur
Ireland
2013
Liberty Global
Virgin Media
UK
2013Actavis
Warner Chilcott
Ireland
2013Perrigo
Elan
Ireland
2014Endo
Paladin
Ireland
2014Theravance Biopharma

Cayman Islands
2014Horizon
Vidarg
Ireland
Pending
Medtronic
Covidien
Ireland
Pending
Mylan
Abbott - genericsNetherlands
Pending
AbbVie
ShireJersey
Pending
Burger King
Tim HortonsCanada

Plans to achieve this include new rules that make it impossible for companies to make intra-company loans to the new overseas parent and that prevent inverted companies from restructuring a foreign subsidiary in order to access its earnings tax-free.

As for the deal with Shire, AbbVie said its board of directors has “not withdrawn or modified its recommendation” to stockholders, and will discuss options at the meeting on October 20.

AbbVie confirmed that if it was to withdraw or modify its recommendation, a deal could still be on the cards as “it would not cause a lapse of AbbVie's offer or terminate the co-operation agreement”.

Following the board meeting AbbVie must convene an additional meeting with stockholders to consider the merger with Shire. The offer will only lapse if the company's stockholders do not adopt the agreement.

Commenting on the announcement Dr Mick Cooper, an analyst at Edison Investment Research, said the news doesn't mean the end of the merger.

“Such an outcome is understandable given the undoubted tax benefits some suitors would accrue, however we believe acquisitions that have solid commercial rationale underpinning them will proceed largely as proposed,” he said.

Article by
Thomas Meek

15th October 2014

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics